Pain Management

Image description

Purdue Pharma launches Hysingla ER

Purdue Pharma on Monday announced the launch of Hysingla ER (hydrocodone bitartrate) extended-release tablets CII. According to the company, the once-daily drug is the first and only hydocodone product to be recognized by the Food and Drug Administration as having properties that deter misuse and abuse via chewing, snorting and injection.

Image description

Egalet acquires pain products Oxaydo and Sprix

Egalet Corp. last week announced the licensing and acquisition of two pain products. Egalet has agreed to license worldwide rights to Oxaydo (oxycodone HCI, USP) tablets for oral use only -CII, the first and only approved immediate-release oxycodone product formulated to deter abuse via snorting from Acura Pharmaceuticals, the company stated.

Image description

FDA approves updated label for Pfizer's Embeda

Pfizer last week announced that the Food and Drug Administration approved a revised label for Embeda (morphine sulfate and naltrexone hydrochloride) extended-release capsules, for oral use, CII, to include abuse-deterrence studies.